Intermediate risk (n = 157) 141 (61.8%) 16 (51.6%)
High risk (n = 41) 38 (16.7%) 3 (9.7%) Total (n = 259) 228 31
allo-SCT, allogeneic stem cell transplantation; ATL-PI, adult T-cell leukemia/lymphoma prognostic index rates of patients with and without strongyloidiasis were 8.2% and 13.0%, respectively.
There was no significant difference in 3yOS between patients with and without strongyloidiasis (P = 0.2000). ATL, adult T-cell leukemia/lymphoma; 3yOS, 3-year overall survival. years, 0.7 years, and 0.3 years, and 3yOS rates were 34.5%, 9.2%, and 12.5% for patients at low, intermediate, and high risk, respectively (P = 0.0001). (B) According to the JCOG-PI, MSTs were 0.9 years and 0.5 years, and 3yOS rates were 22.4% and 7.6% for patients at moderate and high risk, respectively (P = 0.0005).
Abbreviations: ATL, adult T-cell leukemia/lymphoma; ATL-PI, adult T-cell leukemia/lymphoma prognostic index; JCOG-PI, Japan Clinical Oncology Group prognostic index; MST, median survival time; 3yOS, 3-year overall survival
